ASCO 2023 | The national surgical quality improvement program analysis

Shawn Dason, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, provides an overview of the national surgical quality improvement program analysis. The analysis utilized a large population dataset and specifically examined two groups: those who underwent upfront nephrectomy without preoperative systemic therapy and those who had deferred nephrectomy after receiving systemic therapy. The study aimed to address the lack of updated data on perioperative outcomes with the advent of new systemic therapies. The findings indicated that there was minimal difference in perioperative outcomes between the two approaches in the contemporary dataset. This suggests that deferring cytoreductive nephrectomy after a period of upfront systemic therapy is a viable option without significantly impacting surgical complications or perioperative outcomes. However, other factors should still be considered when making treatment decisions for individual patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.